Want to see XCUR full AI Analyst Report?
Top Page
Exicure
(NASDAQ:XCUR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-66.27% Downside)
Action:Reiterated
Date:07/10/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and significant cash burn). Technicals also remain bearish with the stock trading below key moving averages, only partially offset by oversold signals. Corporate events are a modest positive due to strengthened governance and restored Nasdaq filing compliance, but they do not outweigh the fundamental weakness.
Positive Factors
Board refresh & stronger independent oversight
The board expansion and appointment of an independent director plus a formal Compensation Committee strengthen governance and oversight. Improved board composition is a durable control that can reduce operational and governance risk, improve strategic discipline and align executive incentives over the medium term.
Negative Factors
Sustained negative operating cash flow
Persistent negative operating and free cash flow indicate ongoing cash burn with no internal self-funding. Over the next 2–6 months this necessitates external financing or asset sales, which can dilute shareholders or divert management focus from development and commercialization priorities.
Read all positive and negative factors
Positive Factors
Negative Factors
Board refresh & stronger independent oversight
The board expansion and appointment of an independent director plus a formal Compensation Committee strengthen governance and oversight. Improved board composition is a durable control that can reduce operational and governance risk, improve strategic discipline and align executive incentives over the medium term.
Read all positive factors
Exicure (XCUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.15M
Dividend YieldN/A
Average Volume (3M)23.77K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS Growth5.12%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.54
Shares Outstanding6,373,937
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.29
Enterprise Value/Ebitda-1.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Exicure Business Overview & Revenue Model
Company Description
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical eval...
How the Company Makes Money
null...
Exicure Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 500.00K | 0.00 | 28.83M | -483.00K |
| Gross Profit | -263.00K | -460.00K | 500.00K | -1.42M | 26.97M | -483.00K |
| EBITDA | -9.78M | -5.12M | -8.85M | -15.54M | 78.00K | -60.63M |
| Net Income | -9.78M | -4.95M | -9.70M | -16.91M | -2.58M | -64.10M |
Balance Sheet | ||||||
| Total Assets | 12.76M | 14.04M | 15.06M | 11.58M | 23.33M | 64.87M |
| Cash, Cash Equivalents and Short-Term Investments | 2.60M | 3.75M | 12.51M | 816.00K | 8.58M | 39.14M |
| Total Debt | 22.00K | 176.00K | 5.93M | 6.67M | 7.31M | 14.74M |
| Total Liabilities | 10.66M | 10.12M | 8.28M | 8.55M | 8.41M | 53.64M |
| Stockholders Equity | 2.10M | 3.93M | 6.77M | 3.03M | 14.92M | 11.23M |
Cash Flow | ||||||
| Free Cash Flow | -8.10M | -8.56M | -2.91M | -10.36M | -35.67M | -35.79M |
| Operating Cash Flow | -8.10M | -8.55M | -2.91M | -10.36M | -35.66M | -34.82M |
| Investing Cash Flow | 283.00K | -1.81M | 0.00 | -1.08M | 4.70M | 43.09M |
| Financing Cash Flow | 0.00 | 1.60M | 13.40M | 3.67M | -3.10M | 1.12M |
Exicure Technical Analysis
Negative
5.93
Price Trends
2.76
Negative
3.37
Negative
4.13
Negative
Market Momentum
-0.30
Positive
32.93
Neutral
9.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Negative. The current price of 5.93 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.76, and above the 200-day MA of 4.13, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 32.93 is Neutral, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XCUR.
Exicure Risk Analysis
Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Exicure Peers Comparison
UnderperformOutperform
Sector (51)
XCUR
Exicure
1.65
-5.38
-76.53%
UNCY
Unicycive Therapeutics
5.09
0.21
4.30%
CRBU
Caribou Biosciences
1.80
0.10
5.88%
Exicure Corporate Events
Business Operations and StrategyExecutive/Board Changes
Exicure refreshes board with new independent directors
Positive
Jun 30, 2026
On June 24, 2026, Exicure announced that director Ham Jung Kyu had resigned from its board, effective June 30, 2026, with the company stating his departure did not involve any disagreements over operations or policies. On the same date, the board ...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Exicure Regains Nasdaq Compliance After Late Quarterly Filing
Positive
Jun 1, 2026
Exicure, Inc., a Nasdaq-listed biotechnology company transitioning from its original nucleic acid therapy platform to a reoriented portfolio in hematologic diseases, is currently focused on strategic alternatives following a restructuring that hal...
Business Operations and StrategyExecutive/Board Changes
Exicure Strengthens Leadership With New COO and Director
Positive
Apr 10, 2026
On April 8, 2026, Exicure, Inc. appointed Yoontae Han to its board of directors and named him to the audit committee, while elevating existing member Dongho Lee to chair of that committee, reinforcing its governance and audit oversight structure. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.